We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App


13 Jun 2024 - 15 Jun 2024
18 Jun 2024 - 20 Jun 2024

Microdevices Implanted Into Tumors Can Treat Brain Cancer

By HospiMedica International staff writers
Posted on 07 Sep 2023
Print article
Image: The microdevices are implanted in a patient’s tumor during surgery and removed before the surgery is complete (Photo courtesy of 123RF)
Image: The microdevices are implanted in a patient’s tumor during surgery and removed before the surgery is complete (Photo courtesy of 123RF)

Gliomas, a particularly lethal form of brain and spinal cord tumor, pose a formidable challenge for treatment. Developing precise therapies for these tumors is hampered by the difficulty of testing numerous drug combinations in real tumor cells, as patients can only undergo one treatment approach at a time. Now, a groundbreaking solution has emerged in the form of tiny devices, no larger than a grain of rice, capable of conducting multiple experiments concurrently to assess the impact of novel treatments on these hardest-to-treat brain cancers.

Researchers from Brigham and Women's Hospital (Boston, MA, USA) have designed a device for testing glioma treatments in patients suffering from this deadly type of brain cancer. This innovative device, integrated seamlessly into standard surgical procedures, offers unprecedented insights into drug effects on glioma tumors and, importantly, did not cause any adverse reactions in a phase 1 clinical trial. During surgery, these microdevices are implanted directly into the patient's tumor and remain in place for around 2-3 hours. During this time, the device administers minuscule doses of up to 20 drugs into extremely small areas of the brain tumor. Subsequently, the device is removed, and the surrounding tissue is sent to the lab for in-depth analysis. Since the device operates within the patient's body, it provides an unparalleled opportunity to evaluate drug impacts on the tumor microenvironment – the cells immediately adjacent to cancer cells, often composing a significant portion of the tumor mass.

In a recent study, the researchers applied their device to six patients undergoing glioma tumor removal surgery. Remarkably, none of the patients experienced adverse effects from the device. The research team collected invaluable biological data, including how responses change with varying drug concentrations and the molecular changes induced by each drug in the cells. While the study confirmed the device's safety and seamless integration into surgical practice, researchers are now focusing on optimizing glioma therapy using the data collected. They are presently conducting a two-stage procedure in which patients receive the device through minimally invasive surgery 72 hours prior to their main surgery, further advancing the potential of this groundbreaking approach.

“We’re optimistic that this is a new generation approach for personalized medicine,” said co-principal investigator and co-corresponding author Pierpaolo Peruzzi, MD, PhD. “The ability to bring the lab right to the patient unlocks so much potential in terms of the type of information we can gather, which is new and exciting territory for a disease that has very few options at present.”

Related Links:
Brigham and Women's Hospital 

Gold Member
Solid State Kv/Dose Multi-Sensor
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
Trimline Basic

Print article


Critical Care

view channel
Image: The new WHO guidelines include 14 good practice statements and 23 recommendations on key areas for health workers (Photo courtesy of Shutterstock)

WHO Publishes First Global Guidelines to Reduce Bloodstream Infections from Catheter Use

Up to 70% of all inpatients require a catheter, specifically a peripherally inserted catheter (PIVC), at some point during their hospital stay. Patients who receive treatments via catheters are particularly... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.